Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Receivables (2016 - 2025)

Haemonetics has reported Receivables over the past 16 years, most recently at $195.7 million for Q4 2025.

  • Quarterly results put Receivables at $195.7 million for Q4 2025, down 7.66% from a year ago — trailing twelve months through Dec 2025 was $195.7 million (down 7.66% YoY), and the annual figure for FY2025 was $202.7 million, down 1.89%.
  • Receivables for Q4 2025 was $195.7 million at Haemonetics, down from $207.1 million in the prior quarter.
  • Over the last five years, Receivables for HAE hit a ceiling of $213.5 million in Q3 2024 and a floor of $132.4 million in Q2 2021.
  • Median Receivables over the past 5 years was $183.4 million (2022), compared with a mean of $182.1 million.
  • Biggest five-year swings in Receivables: dropped 22.24% in 2021 and later increased 24.57% in 2022.
  • Haemonetics' Receivables stood at $145.7 million in 2021, then rose by 28.82% to $187.7 million in 2022, then rose by 12.74% to $211.6 million in 2023, then grew by 0.16% to $211.9 million in 2024, then fell by 7.66% to $195.7 million in 2025.
  • The last three reported values for Receivables were $195.7 million (Q4 2025), $207.1 million (Q3 2025), and $200.8 million (Q2 2025) per Business Quant data.